Healthcare - Biotechnology - NASDAQ - US
$ 9.26
-6.75 %
$ 1.08 B
Market Cap
-5.54
P/E
CASH FLOW STATEMENT
-247 M
OPERATING CASH FLOW
180 M
INVESTING CASH FLOW
101 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Arcutis Biotherapeutics, Inc.
| Net Income | -262 M |
| Depreciation & Amortization | 1.52 M |
| Capital Expenditures | -428 K |
| Stock-Based Compensation | 38.8 M |
| Change in Working Capital | -23.5 M |
| Others | -5.43 M |
| Free Cash Flow | -247 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (262.1) | (311.5) | (206.4) | (135.7) | (42.0) | (19.3) | (5.0) |
| Depreciation & Amortization | 1.5 | 0.9 | 0.5 | 0.1 | 0.2 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 3.5 | 0.1 | 0 | 0 | 0 |
| Stock Based Compensation | 38.8 | 32.7 | 23.9 | 7.9 | 0.8 | 0.2 | 27 K |
| Other Operating Activities | (1.8) | 30.3 | 0.3 | 0.3 | (0.4) | 2.9 | 0.9 |
| Change in Working Capital | (23.5) | (10.2) | 3.6 | 14.1 | (1.5) | 2.1 | 0.3 |
| Cash From Operations | (247.1) | (257.7) | (174.6) | (113.0) | (42.8) | (14.1) | (3.8) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.4) | (23.3) | (1.0) | (0.3) | (0.3) | 0 | 0 |
| Other Items | 180.7 | (63.9) | (75.0) | (181.5) | (26.0) | (11.5) | 0 |
| Cash From Investing Activities | 180.2 | (87.2) | (76.0) | (181.8) | (26.3) | (11.5) | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 125.0 | 74.0 | 0 | 0 | 0 | 50 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.4 | 0.8 | 0.5 | 1.1 | 93.1 | 61.6 | 14.1 |
| Cash From Financing Activities | 101.3 | 301.8 | 281.9 | 298.1 | 93.1 | 61.6 | 7.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 34.4 | (43.1) | 31.4 | 3.3 | 23.9 | 36.0 | 3.3 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (247.5) | (281.0) | (175.6) | (113.4) | (43.1) | (14.1) | (3.8) |